Oslo, Norway, March 30, 2023 - Lytix Biopharma AS ("Lytix") (Euronext Growth
Oslo: LYTIX), a clinical stage immuno-oncology company, announces that it has
published its Annual Report for 2022, which was approved by the board of
directors on March 29, 2023.


     "In the course of 2022, our unique position in the immune-oncology field
has been confirmed. We bring a novel immunother¬apy approach to the table that
addresses the most fundamental challenge in current immunotherapy: tumor
heterogeneity," says Øystein Rekdal, CEO of Lytix Biopharma.


The Annual Report for 2022 is attached to this notice and is also available on
the company's website, www.lytixbiopharma.com, under Investors. 


For more information, please contact: 
* Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
* Ole Peter Nordby, Head of IR & Communication Manager:
ole.peter.nordby@lytixbiopharma.com



Lytix in brief: 
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient's immune system to fight cancer. The
Company's technology is based on pioneering research in "host defense peptides"
- nature's first line of defense towards foreign pathogens. Lytix Biopharma's
lead product, LTX-315, is a first-in-class oncolytic molecule representing a new
and superior in situ therapeutic vaccination principle to boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapy. LTX-315 target cancer cells and disintegrate their cell
membranes, causing immunogenic cell death and release of a patient's tumor
specific antigens.  This mode of action allows cytotoxic T cells to recognize,
infiltrate, and attack cancer cells. The Company was listed on Euronext Growth
in Oslo in June 2021, following a private placement covered by investors such as
PBM Capital, a US based, healthcare-focused investment firm.